Welcome to our dedicated page for Biomea Fusion SEC filings (Ticker: BMEA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech filings can read like lab notebooks—hundreds of pages of trial protocols, R&D expenses, and dilution clauses. Biomea Fusion (BMEA) adds another layer with its covalent menin-inhibitor pipeline and beta-cell regeneration data. If you’re hunting for the exact moment a dose-escalation update hits EDGAR or need to track when executives sell shares ahead of data read-outs, this page solves the problem.
Stock Titan’s AI reviews every disclosure the second it posts, turning raw text into plain-English notes. The platform flags:
- Form 4 alerts—search “Biomea Fusion insider trading Form 4 transactions” and receive real-time signals
- 10-Q cash-runway and expense trends inside each “Biomea Fusion quarterly earnings report 10-Q filing”
- 8-K material events explained for clinical holds, financing moves, or trial milestones
- Proxy statements outlining “Biomea Fusion executive compensation” and option grants
Each document links to an AI-powered summary that answers common questions—“What new risk factors appear in the annual report?” “How much did R&D grow this quarter?”—so anyone searching “Biomea Fusion SEC filings explained simply” gets an immediate answer. Additional long-tail queries like “Biomea Fusion Form 4 insider transactions real-time”, “Biomea Fusion annual report 10-K simplified”, and “understanding Biomea Fusion SEC documents with AI” are already indexed.
Whether you need to monitor Biomea Fusion executive stock transactions Form 4, compare pipeline spending across quarters, or decode a sudden shelf registration, Stock Titan keeps every filing organized, summarized, and updated in real time. No more combing through PDFs—just clear context for BMEA’s science-driven business model and your next investment decision.
Biomea Fusion, Inc. reporting persons disclosed their beneficial ownership of the company’s common stock. The filing shows that Rainer M. Erdtmann beneficially owns an aggregate of 2,975,224 shares, representing approximately 5.2% of the outstanding class on the basis reported. That total includes 482,404 shares issuable upon exercise of options exercisable within 60 days plus directly held shares and shares held in trusts and for family members.
Related entities Point Sur Investors, LLC and Point Sur Investors Fund I, L.P. directly hold 252,320 and 228,470 shares, respectively (a combined 480,790 shares), over which Mr. Erdtmann has shared voting and dispositive power as the managing member and general partner.
Michael J.M. Hitchcock, who serves as Interim CEO and a director of Biomea Fusion, Inc. (BMEA), was granted a stock option giving him the right to purchase 916,434 shares of common stock at an exercise price of $1.53 per share. The option vests in 16 substantially equal quarterly installments beginning after August 8, 2025 and will be fully vested on August 8, 2029, subject to continued service. The option expires on August 10, 2035 and is reported as directly beneficially owned.
This filing records an executive equity award with a multiyear vesting schedule and a single stated exercise price; the form does not disclose total outstanding shares, prior holdings for this reporting person, or cashless-exercise provisions, so the potential dilution or relative size of the grant cannot be determined from this document alone.
Rainer M. Erdtmann, a director and officer of Biomea Fusion (BMEA), reported multiple late-January 2025 stock transfers and a large option award. On 01/28/2025 he disposed of 40,000 shares and on 01/31/2025 recorded three additional disposals of 10,000 each alongside three indirect acquisitions of 10,000 shares attributed to his children, leaving 643,027 shares held directly following those transactions.
The filing discloses indirect holdings held in Trust 1 (174,614), Trust 2 (1,134,989), Point Sur Investors Fund I, LP (228,470) and Point Sur Investors, LLC (252,320). It also reports a grant of 1,246,989 stock options on 08/11/2025 with a $1.53 exercise price, vesting in 16 quarterly installments beginning 08/08/2025 and fully vesting 08/08/2029, expiring 08/10/2035.
Blue Owl Capital Holdings LP reports beneficial ownership of 3,800,000 shares of Biomea Fusion common stock, representing 6.13% of the outstanding class. The position is composed of 1,300,000 directly held shares and 2,500,000 shares issuable upon exercise of warrants. The filing states the percentage was calculated using the issuer's reported outstanding share count plus the warrants. The reporting person discloses shared voting and shared dispositive power over the reported shares and confirms the securities are held in the ordinary course of business and not to influence control.
FAQ
What is the current stock price of Biomea Fusion (BMEA)?
What is the market cap of Biomea Fusion (BMEA)?
